Natural products against renin-angiotensin system for antifibrosis therapy

Yang, Tian; Chen, Yuanyuan; Liu, Jingru; Zhao, Hui; Vaziri, Nosratola D.; Guo, Yan; Yan, Zhao

doi:10.1016/j.ejmech.2019.06.091

Cited by 35 publications

(21 citation statements)

References 236 publications

(164 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first axis of RAS elevates reactive oxygen species and superoxide levels, impairing endothelial function and microcirculation. The ACE2-Ang (1-7)-MasR axis counteracts the function of the ACE-Ang II-AT1R axis, which decreases inflammation and produces vasodilatation [24]. Dysfunction of ACE2 leads to abnormal activation of the ACE-Ang II-AT1R axis, which subsequently promotes platelet adhesion and aggregation and enhances the risk of thromboembolism in multiple organs including the lungs, brain, heart, kidney, etc.…”

Section: Dysfunctional Ace2mentioning

confidence: 99%

Dysfunctional Coagulation in COVID-19: From Cell to Bedside

Wang

Saguner

et al. 2020

Adv Ther

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which can induce multisystem disease. Human angiotensin-converting enzyme 2 (ACE2) widely expressing in arterial and venous endothelial cells and arterial smooth muscle cells has been identified as a functional receptor for SARS-CoV-2. Dysfunction of ACE2 leads to abnormal activation of the renin-angiotensin system and a systemic endotheliitis that may relate to abnormal coagulation and sepsis. Meanwhile, innate immune response and inflammation activation participate in dysfunctional coagulation. Previous research indicated that dysfunctional coagulation was one of the important risk factors accountable for a high risk of severe disease and death in patients with COVID-19. Understanding the possible mechanisms of dysfunctional coagulation and appropriate anticoagulation therapeutic strategies are important to prevent disease deterioration and reduce fatality rates during the ongoing COVID-19 pandemic.

show abstract

Section: Dysfunctional Ace2mentioning

confidence: 99%

Dysfunctional Coagulation in COVID-19: From Cell to Bedside

Wang

Saguner

et al. 2020

Adv Ther

View full text Add to dashboard Cite

show abstract

“…Traditional Chinese Medicine (TCM) was widely used in clinic and has been cognized an alternative therapeutic strategy for the treatment of various diseases. [1][2][3][4][5][6] Crocus sativus L. is origin from Iran and stigma is used as the medicine for activating blood circulation and eliminating stasis in China. [7] With the development of cultivation, it has been planted successfully in many countries.…”

Section: Introductionmentioning

confidence: 99%

Discrimination of Different Parts of Saffron by Metabolomic‐Based Ultra‐Performance Liquid Chromatography Coupled with High‐Definition Mass Spectrometry

et al. 2019

Chemistry & Biodiversity

View full text Add to dashboard Cite

In this study, the metabolite profiling of three different parts of Crocus sativus L. was measured by using ultra‐performance liquid chromatography‐quadrupole time‐of‐flight mass spectrometry (UPLC‐QTof‐MS/MS). Multivariate statistical analysis was used to distinguish among the samples from different parts. A total of 54 compounds were identified in tepals, stigmas and stamens by UPLC‐QTof‐MS/MS. The results stated that chemical characteristics of saffron were obviously diverse in terms of the parts of flower. Through analysis, coniferin and crocin‐2 were special components in stigmas when compared to tepals and stamens. The content of flavonoids was high in tepals when compared with the stigmas. The tepal of saffron may processed as a source of flavonoids in the future. The research provided the basis for the theory that only the stigma can be used as medicine.

show abstract

“… 31 , 32 Clinically, angiotensin receptor blocker and angiotensin-converting enzyme inhibitor are the first-line therapy in CKD. 33 – 36 Even if they could inhibit renal fibrosis, they have some non-negligible side effects and are invalid in certain circumstances. 37 In addition, few drugs target fibrogenesis specifically, which is hindered by the lack of an effective therapeutic target.…”

Section: Discussionmentioning

confidence: 99%

Poricoic acid A as a modulator of TPH-1 expression inhibits renal fibrosis via modulating protein stability of β-catenin and β-catenin-mediated transcription

Chen

et al. 2020

Therapeutic Advances in Chronic Disease

Self Cite

View full text Add to dashboard Cite

Background: Renal fibrosis is the common feature of chronic kidney disease (CKD). However, few drugs specifically target fibrogenesis due to the lack of an effective therapeutic target. Hence, it is urgent to find a therapeutic strategy that inhibits renal fibrosis. Here, we identified that poricoic acid A (PAA) as the modulator of tryptophan hydroxylase-1 (TPH-1), the key enzyme in tryptophan metabolism, exerted potent anti-fibrotic effects in the kidney. Methods: Lentiviral vector, luciferase reporter activity assay and co-immunoprecipitation were used. The animal model of unilateral ureteral obstruction and adenine-induced chronic renal failure as well as transforming growth factor (TGF)-β1-treated epithelial cells NRK-52E and fibroblasts NRK-49F were used. Results: TPH-1 was gradually decreased during CKD progression, while PAA treatment significantly increased TPH-1 expression to suppress renal fibrosis. Pharmacological overexpression of TPH-1 by PAA treatment exhibited anti-fibrosis and was linked to Wnt/β-catenin signaling activity. TPH-1 exhibited anti-fibrotic effects by suppressing epithelial cell injury and fibroblast activation, and PAA promoted TPH-1 expression and then suppressed the Wnt/β-catenin signaling pathway via regulating the protein stability of β-catenin and β-catenin-mediated transcription. TPH-1 overexpression enhanced the anti-fibrotic effects of PAA, while TPH-1 deficiency weakened the anti-fibrotic effects of PAA, indicating that TPH-1 was required for the anti-fibrotic effects of PAA. Conclusion: PAA as a modulator of TPH-1 expression attenuated renal fibrosis through regulating the Wnt/β-catenin signaling pathway by acting on the protein stability of β-catenin and β-catenin-mediated transcription. TPH-1 was required for PAA to exert anti-fibrosis.

show abstract

Natural products against renin-angiotensin system for antifibrosis therapy

Cited by 35 publications

References 236 publications

Dysfunctional Coagulation in COVID-19: From Cell to Bedside

Dysfunctional Coagulation in COVID-19: From Cell to Bedside

Discrimination of Different Parts of Saffron by Metabolomic‐Based Ultra‐Performance Liquid Chromatography Coupled with High‐Definition Mass Spectrometry

Poricoic acid A as a modulator of TPH-1 expression inhibits renal fibrosis via modulating protein stability of β-catenin and β-catenin-mediated transcription

Contact Info

Product

Resources

About